Remodeling MMPIs


Matrix metalloproteinase inhibitors will be approved as drugs, probably this year, but questions remain concerning their specificity, bioavailability, and potential long-term toxicity

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Gearing, A.J.H., et al. 1994. Processing of tumour necrosis factor—A precursor by metalloproteinases. Nature 370: 555–557.

  2. 2

    Mohler, K.M., et al. 1994. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing, Nature 370: 218–220.

  3. 3

    Murphy, G. and Docherty, A.J.P. 1992. The Matrix metalloproteainases and their inhibitors. Am. J. Respir. Cell Mol. Biol. 7: 120–125.

  4. 4

    Docherty, A.J.P., et al. 1992. The matrix metalloproteinases and their natural inhibitors: Prospects for treating degenerative tissue disease. TIBETECH 10: 200–207.

  5. 5

    Sato, H., et al. 1994. A matrix metalloproteinase expressed on flie surface of invasive tumour cells. Nature 370: 61–65,

  6. 6

    Taraboletti, G., et al. 1995. Inhibition of aogiogenesis and murine hemangioma growth by Batimastat, a synthetic inhibitor of matrix metalloproteuiases. NCI 87: 293–298.

  7. 7

    Golub, L.M., et al. 1991. Tetracyclines inhibit connective tissue breakdown: New therapeutic implications for an old family of drugs. Crit. Rev. Oral. Biol. Med. 2: 297–322.

Download references

Author information



Rights and permissions

Reprints and Permissions

About this article

Cite this article

Hodgson, J. Remodeling MMPIs. Nat Biotechnol 13, 554–557 (1995).

Download citation

Further reading